These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Camilleri M Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():48-53. PubMed ID: 10429740 [TBL] [Abstract][Full Text] [Related]
7. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Baker DE Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Schoenfeld P Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938 [TBL] [Abstract][Full Text] [Related]
9. Tegaserod for constipation-predominant irritable bowel syndrome. Kale-Pradhan PB; Wilhelm SM Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916 [TBL] [Abstract][Full Text] [Related]
10. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Farthing MJ Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922 [TBL] [Abstract][Full Text] [Related]
11. Drug therapy options for patients with irritable bowel syndrome. Talley NJ Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911 [TBL] [Abstract][Full Text] [Related]
12. The brain-gut axis in irritable bowel syndrome--clinical aspects. Mach T Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682 [TBL] [Abstract][Full Text] [Related]
13. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
14. The spectrum of irritable bowel syndrome: A clinical review. Gilkin RJ Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Rahimi R; Nikfar S; Abdollahi M Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935 [TBL] [Abstract][Full Text] [Related]